thiazoles has been researched along with Hematologic Malignancies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almstead, NG; Arasu, T; Babiak, J; Branstrom, A; Cao, L; Cintron, K; Colacino, JM; Davis, TW; Du, J; Furia, B; Graci, JD; Hedrick, J; Hwang, S; Jacobson, A; Kim, MJ; Kong, R; Lennox, W; Li, W; Ma, J; Moon, YC; Peltz, SW; Petruska, J; Qi, H; Risher, N; Romfo, C; Sheedy, J; Trotta, C; Weetall, M; Yeh, S | 1 |
| Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A | 1 |
| Nishida, T; Tsukazaki, K | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Adamson, PC; Agrawal, S; Aplenc, R; Balis, FM; Blaney, SM; Ingle, AM; Shusterman, S; Strauss, LC; Sun, J; Wright, JJ | 1 |
| Amrein, PC | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Figuerres, E; Kletzel, M; Olszewski, M | 1 |
| Bokemeyer, C; Corbin, AS; Deininger, MW; Druker, BJ; Griffith, D; Heinrich, MC; Lee, FY; Schittenhelm, MM; Schroeder, A; Shiraga, S | 1 |
3 review(s) available for thiazoles and Hematologic Malignancies
| Article | Year |
|---|---|
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Topics: Dasatinib; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
1 trial(s) available for thiazoles and Hematologic Malignancies
| Article | Year |
|---|---|
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Hospitals, Pediatric; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maximum Tolerated Dose; Neoplasms; Patient Selection; Pediatrics; Philadelphia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Thiazoles; Treatment Outcome; Young Adult | 2011 |
6 other study(ies) available for thiazoles and Hematologic Malignancies
| Article | Year |
|---|---|
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dihydroorotate Dehydrogenase; Hematologic Neoplasms; Humans; Imidazoles; K562 Cells; Mice; Oxidoreductases Acting on CH-CH Group Donors; Thiazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Humans; Hypoxanthine; Male; Middle Aged; Pilot Projects; Prospective Studies; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine; Xanthine Oxidase | 2014 |
[Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Topics: Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Thiazoles | 2015 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
A flow cytometric technique using thiazole orange to detect platelet engraftment following pediatric stem-cell transplants.
Topics: Adolescent; Adult; Benzothiazoles; Blood Platelets; Bone Marrow Transplantation; Child; Child, Preschool; Fetal Blood; Flow Cytometry; Fluorescent Dyes; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Infant, Newborn; Platelet Count; Platelet Transfusion; Predictive Value of Tests; Quinolines; Reproducibility of Results; RNA; Thiazoles; Thrombocytopenia; Treatment Outcome | 2001 |
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Topics: Amino Acid Substitution; Animals; Benzamides; Cell Growth Processes; Cell Survival; CHO Cells; Cricetinae; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Isoenzymes; MAP Kinase Signaling System; Mice; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |